期刊
INTERNATIONAL JOURNAL OF CARDIOLOGY
卷 168, 期 3, 页码 1822-1831出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2013.07.117
关键词
Aortic stenosis; Transcutaneous aortic valve implantation; Transcatheter aortic valve implantation; Percutaneous aortic valve replacement; Prosthetic valves
资金
- The Prince Charles Hospital Foundation (TPCHF)
- University of Queensland (UQ)
- Office of Health and Medical Research (OHMR)
The efficacy of transcatheter aortic valve implantation (TAVI) in high surgical risk and inoperable patients with severe aortic stenosis (AS) is rapidly gaining credibility with an ever-expanding body of supporting evidence. The potential of TAVI to be a treatment option for a significant cohort of patients with aortic stenosis has fuelled a drive for the optimum device and resulted in exponential advances in the technology with a focus on adverse event minimization and procedural simplification. Consequently, a plethora of new transcatheter valve choices are nowavailable for clinical study or in the pipeline. The evaluation of past, current and emerging devices allows for an appreciation of the design considerations involved in this process and an insight to the future direction of the technology. Crown Copyright (C) 2013 Published by Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据